Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPJ-101CA maintenance therapy for newly diagnosed high-risk neuroblastoma
jRCT2031220687Completed
- Sponsor
- Sun Pharma
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of isotretinoin in neuroblastoma, sponsored by Sun Pharma. Primary endpoint: Rate of serious adverse events related to SPJ-101-CA. Started Mar 2023; status: completed.
02
Drugs
isotretinoin
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCT2031220687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220687.